Introduction

In pharmacovigilance (PV), the accuracy and integrity of safety data are fundamental to protecting patient health and ensuring regulatory compliance. One critical yet sometimes underestimated activity is duplicate case management. Duplicate Individual Case Safety Reports (ICSRs) can arise from multiple reporting sources, follow-ups submitted as new cases, or parallel reporting pathways across affiliates and partners. If not properly identified and managed, duplicates can distort safety signals, compromise regulatory submissions, and undermine benefit–risk evaluations.

This article explores the importance of duplicate case management in PV, highlighting its regulatory significance, operational responsibilities, and procedural requirements.

Understanding Duplicate Cases in Pharmacovigilance

Duplicate cases occur when the same adverse event related to the same patient and product is reported more than once. These reports may originate from different sources such as healthcare professionals, patients, literature, distributors, or regulatory authorities.

Common causes of duplicate cases include:

• Multiple reporters describing the same event
• Follow-up information submitted as a new initial report
• Reporting by both local affiliates and global partners
• Literature cases overlapping with spontaneous reports

Without systematic detection, duplicate cases may be mistakenly treated as independent events, leading to inaccurate safety data.

Regulatory Importance of Duplicate Case Management

Regulatory authorities such as the EMA, FDA, and national competent authorities explicitly require Marketing Authorization Holders (MAHs) to maintain robust processes for duplicate detection and reconciliation.

From a regulatory perspective, effective duplicate case management:

• Ensures compliance with Good Pharmacovigilance Practices (GVP)
• Prevents artificial inflation of case counts
• Supports accurate aggregate reporting (e.g., PSURs/PBRERs)
• Maintains data integrity in safety databases (e.g., EudraVigilance, VigiBase)

Failure to appropriately manage duplicates may result in regulatory findings, inspection observations, or misinterpretation of a product’s safety profile.

Roles and Responsibilities in Duplicate Case Management

Duplicate case management is a shared responsibility across PV functions and partners:

• Case Processing Teams: Perform routine duplicate checks during case intake and follow-up processing using predefined criteria.
• PV Physicians / Safety Scientists: Assess medical plausibility when determining whether cases represent true duplicates.
• PV Quality Assurance: Ensure SOPs and training adequately address duplicate detection and documentation.
• Affiliates and Partners: Communicate and reconcile potential duplicates across reporting entities.

Clear role definition and escalation pathways are essential to ensure timely and consistent decisions.

Procedures and Tools for Identifying Duplicate Cases

Effective duplicate detection relies on a combination of procedural controls and technical tools. Key elements include:

• Comparison of patient identifiers (age, sex, initials)
• Event characteristics (event terms, onset dates, outcomes)
• Product details (brand name, batch number, indication)
• Reporter information and reporting source
• Database-supported duplicate search functionalities

Once identified, duplicates must be clearly linked, documented, and justified, with one case designated as the primary record while maintaining traceability to all related reports.

Impact on Signal Detection and Risk Assessment

Duplicate cases can significantly affect signal detection and benefit–risk evaluation if not properly managed. Artificial duplication may:

• Create false safety signals
• Mask true safety trends
• Bias frequency calculations
• Compromise regulatory decision-making

Accurate duplicate management ensures that safety signals are based on true case counts, enabling reliable risk assessment and appropriate risk minimization measures.

Best Practices for Robust Duplicate Case Management

To maintain a high-quality PV system, organizations should:

• Establish detailed SOPs for duplicate detection and reconciliation
• Train PV staff regularly on duplicate identification criteria
• Perform periodic quality reviews and audits
• Ensure effective communication between global and local PV teams
• Document all duplicate decisions with clear scientific rationale

These practices strengthen overall PV compliance and inspection readiness.

Key Takeaways

• Duplicate case management is essential for data integrity in pharmacovigilance
• Poor duplicate control can distort safety signals and regulatory reporting
• Clear roles, SOPs, and trained personnel are critical
• Robust duplicate management supports accurate benefit–risk evaluation
• Regulators expect documented, consistent, and auditable duplicate processes